Amiodarone, digoxin and adenosine
The pharmacology behind three drugs that don't fit neatly into Vaughan Williams. Amiodarone's huge volume of distribution, iodine load and thyroid effects; digoxin's Na/K-ATPase mechanism, renal clearance and P-glycoprotein interactions; adenosine's 10-second half-life and its A1 receptor effects on the AV node.
Tier 2Medical sciences concept
Written with AI assistance and fact-checked against the sources below. For exam study, not clinical decisions. How notes are made
Loading the rest of the note…
Finished reading?
Sources
- Therapeutic Guidelines: CardiovascularAU/NZTherapeutic Guidelines Ltd
- Australian Medicines HandbookAU/NZAustralian Medicines Handbook Pty Ltd, 2026
- National Heart Foundation of Australia and Cardiac Society of Australia and New Zealand Australian clinical guidelines for the diagnosis and management of atrial fibrillation 2018AU/NZNational Heart Foundation of Australia and CSANZ (Heart, Lung and Circulation), 2018
- 2024 ESC Guidelines for the management of atrial fibrillationEuropean Society of Cardiology, 2024
- 2018 European Thyroid Association guidelines for the management of amiodarone-associated thyroid dysfunctionEuropean Thyroid Journal (Bartalena et al., 2018;7:55-66), 2018
- The effect of digoxin on mortality and morbidity in patients with heart failure (DIG trial)New England Journal of Medicine (Digitalis Investigation Group, 1997;336:525-33), 1997
- Last updated
- 14 November 2026
What changed
- 14 November 2026 Turnstile bot check on sign-in and signed-out feedback